Vianautis Information

ViaNautis is revolutionising genetic medicine delivery with polyNaut®, its targeted polymer nanovesicles (tPNVs) across multiple indications. polyNaut® provides a versatile, plug-and-play solution for nanobody-based receptor-mediated delivery of DNA and mRNA to any cell type. By leveraging the broad applicability of tPNVs, ViaNautis is advancing a pipeline across CNS, immunology, oncology and respiratory diseases. With polyNaut®, ViaNautis has built a differentiated non-viral delivery platform – targeted, safe, convenient, redosable and scalable – that promises to widen the reach of genetic medicines to more people in need. The Company is backed by blue-chip investors, including 4BIO Capital, BGF and UCB Ventures, and has strategic partnerships with Eli Lilly and the Cystic Fibrosis Foundation. For further information, please visit: https://vianautis.com/